The content on this site is intended for healthcare professionals only
Minimally invasive surgery was gradually introduced in liver surgery since 1992. It was initially performed for benign and cystic lesions and then for malignant disease. This video presentation illustrates the state of the art of minimally invasive surgery for liver malignancy by reviewing both laparoscopic and robotic experiences of the literature.
New classification for identifying HR myeloma based on cytogenetic abnormalities
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Use of bispecifics and CAR T cells in South America
Revolutionising myeloma treatment through immune profiling
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
